Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT)

Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT)

Item

http://www.wikidata.org/entity/Q33556796

Q33556796

about

Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus Effects of Metformin on Tissue Oxidative and Dicarbonyl Stress in Transgenic Spontaneously Hypertensive Rats Expressing Human C-Reactive Protein Minireview: Challenges and opportunities in development of PPAR agonists High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazone Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.High-sensitivity C-reactive protein concentrations among patients with and without diabetes in a multiethnic population of Singapore: CREDENCE Study Therapeutic approaches to target inflammation in type 2 diabetes Comparative Effects of Glibenclamide and Metformin on C-Reactive Protein and Oxidant/Antioxidant Status in Patients with Type II Diabetes Mellitus.Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions.Diabetes medications: Impact on inflammation and wound healing Obesity, inflammation, and cardiovascular risk.Sex and gender influences on pharmacological response: an overview.The role of inflammatory biomarkers in developing targeted cardiovascular therapies: lessons from the cardiovascular inflammation reduction trials.Associations between self-reported diabetes and 78 circulating markers of inflammation, immunity, and metabolism among adults in the United States Combined high-fat-resveratrol diet and RIP140 knockout mice reveal a novel relationship between elevated bone mitochondrial content and compromised bone microarchitecture, bone mineral mass, and bone strength in the tibia.Diabetic silkworms for evaluation of therapeutically effective drugs against type II diabetes.Metformin use and its effect on gastric cancer in patients with type 2 diabetes: A systematic review of observational studies.Effect of pioglitazone versus metformin on cardiovascular risk markers in type 2 diabetes.

P2860

Q24186667-E641DEB7-DCEA-4B53-8E59-81945037BE2E Q24202505-95AFB00C-73B3-4DB5-8AD6-3ECD1B78626E Q24236456-FDC87DE0-AC69-4D57-9529-A3A50ACB51AC Q28550686-12B9F5D6-D34B-43E7-A09E-748114279728 Q33631921-D89E4509-6729-42FE-921A-A3FAB38B1460 Q33979763-F78F736D-E631-43D5-B97E-9F1817A0BDFE Q34083400-B90D191C-A8B3-4A26-BB4F-4299C614D140 Q34452976-07EAB983-1F91-4FAC-BBF6-BE141139D657 Q34620612-DB8476B5-F23E-465E-B8E2-DDE81951AD44 Q35581498-6ADC7393-DE4D-43B9-A13E-0E8F2F22FAC1 Q35778247-986387CF-53A0-4AFD-84BF-B8CDABCF91C5 Q36261125-C55B3AF4-3A3E-4415-88E6-B6CDD4809E40 Q36805643-D4672E18-4BDD-47D9-8474-A9DFE3A62F26 Q37702091-E4CE38B7-473D-4748-8FC2-C5BDE4D18F28 Q38214338-772759C9-35D3-4ECA-941B-0EA18C19A13A Q38593722-B6615F2E-BF82-4633-A635-4EA48F66A454 Q38650328-7C311C50-7CE9-4A34-97CE-38724036CE9A Q39896236-B8D9DFAF-068E-4B7E-B128-CE7EF2F74A1E Q41349411-0E87CB70-5FCF-4890-8662-345AEC71CF7F Q49183232-78A0B9D5-E1C9-45F7-BFEF-1F5FEA518515 Q51345495-9F9CE32B-6579-4485-9E2F-4749AF41F60F

P2860

Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT)

Item

http://www.wikidata.org/entity/Q33556796

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

name

Rosiglitazone decreases C-reac ...... come Progression Trial (ADOPT)

@ast

Rosiglitazone decreases C-reac ...... come Progression Trial (ADOPT)

@en

Rosiglitazone decreases C-reac ...... etes Outcome Progression Trial

@nl

type

Item

label

Rosiglitazone decreases C-reac ...... come Progression Trial (ADOPT)

@ast

Rosiglitazone decreases C-reac ...... come Progression Trial (ADOPT)

@en

Rosiglitazone decreases C-reac ...... etes Outcome Progression Trial

@nl

prefLabel

Rosiglitazone decreases C-reac ...... come Progression Trial (ADOPT)

@ast

Rosiglitazone decreases C-reac ...... come Progression Trial (ADOPT)

@en

Rosiglitazone decreases C-reac ...... etes Outcome Progression Trial

@nl

P1476

Rosiglitazone decreases C-reac ...... come Progression Trial (ADOPT)

@en

P2093

Barbara G Kravitz

http://www.w3.org/2001/XMLSchema#string

Dahong Yu

http://www.w3.org/2001/XMLSchema#string

Diabetes Outcome Progression Trial (ADOPT) Study Group

http://www.w3.org/2001/XMLSchema#string

Giancarlo Viberti

http://www.w3.org/2001/XMLSchema#string

Gitanjali Paul

http://www.w3.org/2001/XMLSchema#string

Rury R Holman

http://www.w3.org/2001/XMLSchema#string

Steven M Haffner

http://www.w3.org/2001/XMLSchema#string

William H Herman

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs

Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial

Effect of torcetrapib on the progression of coronary atherosclerosis

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels.

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.

Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance

P304

177-183

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC09-1661

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

John M. Lachin

Steven E. Kahn

Bernard Zinman

P577

2009-10-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26875884

http://www.w3.org/2001/XMLSchema#string

P698

19808911

http://www.w3.org/2001/XMLSchema#string

P921

metformin

weight gain

P932

2797969

http://www.w3.org/2001/XMLSchema#string

Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT)

about

P2860

P2860

Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT)

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P921

P932